Fusion Pharmaceuticals Inc. Common Shares
FUSN
FUSN was delisted on the 3rd of June, 2024.
32 hedge funds and large institutions have $116M invested in Fusion Pharmaceuticals Inc. Common Shares in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
20% less funds holding
Funds holding: 40 → 32 (-8)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
47% less capital invested
Capital invested by funds: $221M → $116M (-$105M)
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.19M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$749K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$554K |
| 4 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
+$178K |
| 5 |
E
Ergoteles
New York
|
+$68.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.52M |
| 2 |
Millennium Management
New York
|
-$213K |
| 3 |
PA
Perceptive Advisors
New York
|
-$172K |
| 4 |
Goldman Sachs
New York
|
-$160K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$108K |
FUSN Hedge Fund Activity: Q4 2021 in Review
32 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q4 2021, worth a combined $116M — down 47% from $221M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of FUSN and 3 opened new positions — a net loss of 7 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Point72 Asset Management, adding an estimated $1.19M. The largest seller was BlackRock, cutting an estimated $2.52M.
- 32 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q4 2021, down from 40 in Q3 2021.
- Funds reported $116M of Fusion Pharmaceuticals Inc. Common Shares stock for Q4 2021, down 47% quarter-over-quarter.
- 3 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q4 2021 and 10 closed out, a net change of -7 holders.
- The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q4 2021 was Point72 Asset Management, an estimated $1.19M added.
- The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q4 2021 was BlackRock, an estimated $2.52M sold.
Based on aggregated 13F filings for Q4 2021.